A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF [clinicaltrials:NCT02411786]

Bio2RDF identifier

NCT02411786

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT02411786

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT02411786

anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]

40

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT02411786 arm group 00d33d46c75202a81fb9f1bf215bc652 [clinicaltrials_resource:NCT02411786/arm-group/00d33d46c75202a81fb9f1bf215bc652]

NCT02411786 arm group 17c5f88e442f2344f0815c664d2da34b [clinicaltrials_resource:NCT02411786/arm-group/17c5f88e442f2344f0815c664d2da34b]

NCT02411786 arm group 6569e2e8a3579891de43d7ae32165de2 [clinicaltrials_resource:NCT02411786/arm-group/6569e2e8a3579891de43d7ae32165de2]

NCT02411786 arm group d76a9932fa7c0b4030e6889b44ef004e [clinicaltrials_resource:NCT02411786/arm-group/d76a9932fa7c0b4030e6889b44ef004e]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:2ecd7fcb43dd0bf0b423bf9f9ab12c32

brief summary [clinicaltrials_vocabulary:brief-summary]

The purpose of this stu ...... onse against prostate cancer.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

A Phase I Study of a DNA Vacci ...... nding Domain (AR LBD) +/-GMCSF

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Number and severity of adverse events following serial intradermal vaccinations of a DNA vaccine encoding AR LBD, with or without GM-CSF as an adjuvant, in patients with metastatic prostate cancer From first immunization to Week 72 [clinicaltrials_resource:8fef7c5b60ab9f0a9ab59be32aa75e83]

Number and severity of adverse events following serial intradermal vaccinations of a DNA vaccine encoding AR LBD, with or without GM-CSF as an adjuvant, in patients with metastatic prostate cancer From first immunization to Week 72 [clinicaltrials_resource:fd927983585c1a573ba7195708bf6a23]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Number and severity of adverse events following serial intradermal vaccinations of a DNA vaccine encoding AR LBD, with or without GM-CSF as an adjuvant, in patients with metastatic prostate cancer From first immunization to Week 72 [clinicaltrials_resource:40b2c10f999c56214863b05a2e5138a5]

Number and severity of adverse events following serial intradermal vaccinations of a DNA vaccine encoding AR LBD, with or without GM-CSF as an adjuvant, in patients with metastatic prostate cancer From first immunization to Week 72 [clinicaltrials_resource:6354b2edae055f4c715b50c98ebeeb89]

Number and severity of adverse events following serial intradermal vaccinations of a DNA vaccine encoding AR LBD, with or without GM-CSF as an adjuvant, in patients with metastatic prostate cancer From first immunization to Week 72 [clinicaltrials_resource:7155fd830ba65d4b967768bf1c4f1467]

Number and severity of adverse events following serial intradermal vaccinations of a DNA vaccine encoding AR LBD, with or without GM-CSF as an adjuvant, in patients with metastatic prostate cancer From first immunization to Week 72 [clinicaltrials_resource:d409e8f5b0e99ea41ca3cccff0b0a005]

Number and severity of adverse events following serial intradermal vaccinations of a DNA vaccine encoding AR LBD, with or without GM-CSF as an adjuvant, in patients with metastatic prostate cancer From first immunization to Week 72 [clinicaltrials_resource:f31a53e1d81eb20ac08fd9e9ba0c5053]

Number and severity of adverse events following serial intradermal vaccinations of a DNA vaccine encoding AR LBD, with or without GM-CSF as an adjuvant, in patients with metastatic prostate cancer From first immunization to Week 72 [clinicaltrials_resource:f4e0e1bddd3d9d8b40b17cc2f9827c1f]

collaborator [clinicaltrials_vocabulary:collaborator]

University of Wisconsin, Madison [clinicaltrials_resource:02047e0096c92af4a69eaa4490fe8a82]

completion date [clinicaltrials_vocabulary:completion-date]

2022-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT02411786 [clinicaltrials_resource:ff2a0e111aa6b81eef2a139cfdef3407]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2015-03-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

gm-csf [clinicaltrials_resource:b041eabdddf9209f2e573f4645485c74]

pTVG-AR [clinicaltrials_resource:e2fe4dcb647ace75d0d2f751402c5562]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

No

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-08-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

University of Wisconsin, Madison [clinicaltrials_resource:02047e0096c92af4a69eaa4490fe8a82]

location [clinicaltrials_vocabulary:location]

University of Wisconsin Carbone Cancer Center [clinicaltrials_resource:d37076225aa45c039be9322086809dca]

nct id [clinicaltrials_vocabulary:nct-id]

NCT02411786

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

4

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Phase I Study of a DNA Vacci ...... ith Metastatic Prostate Cancer

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

UW14072

http://www.w3.org/2001/XMLSchema#string

overall official [clinicaltrials_vocabulary:overall-official]

Douglas G. McNeel, M.D., Ph.D. [clinicaltrials_resource:0a47cb18179973f82affe14704aebbf1]

overall status [clinicaltrials_vocabulary:overall-status]

Active, not recruiting [clinicaltrials_resource:a6bc1606956390bcd6a391faced78809]

oversight [clinicaltrials_vocabulary:oversight]

United States: Data and Safety Monitoring Board [clinicaltrials_resource:3208c9fa404036d51df28aa9291f470d]

phase [clinicaltrials_vocabulary:phase]

Phase 1 [clinicaltrials_resource:ee4650e51426c7487977eeea8e7e6850]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2019-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

secondary id [clinicaltrials_vocabulary:secondary-id]

5P30CA014520-40

http://www.w3.org/2001/XMLSchema#string

source [clinicaltrials_vocabulary:source]

University of Wisconsin, Madison [clinicaltrials_resource:02047e0096c92af4a69eaa4490fe8a82]

start date [clinicaltrials_vocabulary:start-date]

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT02411786 study design [clinicaltrials_resource:3f82ec52b8dd565624d2f3aa14ebcbd7]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT02411786

verification date [clinicaltrials_vocabulary:verification-date]

2015-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT02411786

http://www.w3.org/2001/XMLSchema#string

title

A Phase I Study of a DNA Vacci ...... nding Domain (AR LBD) +/-GMCSF

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

A Phase I Study of a DNA Vacci ...... F [clinicaltrials:NCT02411786]

@en